Cargando…

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison

OBJECTIVE: The aim of this meta-analysis was to compare the efficacy and safety of infliximab-biosimilar and other available biologicals for the treatment of rheumatoid arthritis (RA), namely abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baji, Petra, Péntek, Márta, Czirják, László, Szekanecz, Zoltán, Nagy, György, Gulácsi, László, Brodszky, Valentin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046078/ https://www.ncbi.nlm.nih.gov/pubmed/24832836 http://dx.doi.org/10.1007/s10198-014-0594-4

Ejemplares similares

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
por: Baji, Petra, et al.
Publicado: (2014)

Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data
por: Brodszky, Valentin, et al.
Publicado: (2017)

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2014)

The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
por: Gulácsi, László, et al.
Publicado: (2017)

Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
por: Gulácsi, László, et al.
Publicado: (2017)

Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary
por: Tamás, Gertrúd, et al.
Publicado: (2014)

Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data
por: Baji, Petra, et al.
Publicado: (2020)

Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies
por: Zrubka, Zsombor, et al.
Publicado: (2019)

Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary
por: Péntek, Márta, et al.
Publicado: (2019)

A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases
por: Zrubka, Zsombor, et al.
Publicado: (2019)

Acceptable health and ageing: results of a cross-sectional study from Hungary
por: Péntek, Márta, et al.
Publicado: (2020)

Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS
por: Zrubka, Zsombor, et al.
Publicado: (2019)

Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study
por: Nagy, György, et al.
Publicado: (2022)

Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease
por: Mesko, Bertalan, et al.
Publicado: (2013)

Access to biologicals in Crohn’s disease in ten European countries
por: Péntek, Márta, et al.
Publicado: (2017)

Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs
por: Péntek, Márta, et al.
Publicado: (2017)

Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study
por: Zrubka, Zsombor, et al.
Publicado: (2020)

Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary
por: Rencz, Fanni, et al.
Publicado: (2019)

Cost-of-illness studies in nine Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2019)

Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary
por: Baji, Petra, et al.
Publicado: (2020)

Psychometric properties of the Hungarian version of the eHealth Literacy Scale
por: Zrubka, Zsombor, et al.
Publicado: (2019)

Eliciting preferences for outpatient care experiences in Hungary: A discrete choice experiment with a national representative sample
por: Brito Fernandes, Óscar, et al.
Publicado: (2020)

Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50–70: a cross-sectional study on a representative sample of the Hungarian general population
por: Baji, Petra, et al.
Publicado: (2021)

The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
por: Talotta, Rossella, et al.
Publicado: (2017)

The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys
por: Baji, Petra, et al.
Publicado: (2019)

Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey
por: Lucevic, Armin, et al.
Publicado: (2019)

Patient experiences with outpatient care in Hungary: results of an online population survey
por: Brito Fernandes, Óscar, et al.
Publicado: (2019)

Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample
por: Brito Fernandes, Óscar, et al.
Publicado: (2021)

Epidemiology and patients’ self-reported knowledge of implantable medical devices: Results of a cross-sectional survey in Hungary
por: Hölgyesi, Áron, et al.
Publicado: (2023)

Validation of the Musculoskeletal Health Questionnaire in a general population sample: a cross-sectional online survey in Hungary
por: Hölgyesi, Áron, et al.
Publicado: (2022)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
por: Waller, John, et al.
Publicado: (2017)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Changes in Equity in Out-of-pocket Payments during the Period of Health Care Reforms: Evidence from Hungary
por: Baji, Petra, et al.
Publicado: (2012)

Exploring consumers’ attitudes towards informal patient payments using the combined method of cluster and multinomial regression analysis - the case of Hungary
por: Baji, Petra, et al.
Publicado: (2013)

Does the Implementation of Official User Charges Help to Eradicate Informal Payments – Lessons to be Learnt from the Hungarian Experience
por: Baji, Petra, et al.
Publicado: (2015)

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13
por: Sakane, Hideo, et al.
Publicado: (2022)

The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan
por: Alawneh, Khaldoon, et al.
Publicado: (2022)

Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis
por: Póliska, Szilárd, et al.
Publicado: (2019)

Vasculogenesis in rheumatoid arthritis
por: Szekanecz, Zoltán, et al.
Publicado: (2010)

Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis
por: Oláh, Csaba, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ua0ajn4fpg987055mqc5d4le6b